Product Name

Taltz 80 Mg/Ml, Immunosuppressant, Prefilled Single Dose - 1 Pc

Scientific Name

Ixekizumab

Category of Taltz

Immunosuppressant

Mechanism of action of Ixekizumab

Ixekizumab is a humanized monoclonal antibody (IgG) that selectively binds to interleukin 17A (IL-17A); this prevents interleukin 17A from binding to the IL-17 receptor. Thus, this attenuates an inflammatory response mediated by interleukin 1.

Therapeutic Indications of Taltz

It is indicated for the treatment of patients aged six years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
It is also indicated in adult patients with active psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis with objective signs of inflammation.

Method of Administration of Taltz

TALTZ is administered by subcutaneous injection. The recommended dose is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.
TALTZ is administered by subcutaneous injection every 4 weeks (Q4W).
Doses may be changed in special conditions so always follow your doctor's or pharmacist's instructions.
If you take more than you should, talk to a doctor or go to the hospital straight away.
If you forget to take a dose, take it as soon as you remember it unless it is nearly time for your next dose.
Do not take a double dose (two doses at the same time) to make up for the forgotten dose.

Undesirable Side Effects of Taltz

injection site reactions, such as pain.
hives
fungal infections, such as athlete's foot.
nausea.
upper respiratory infections, such as the common cold.
pink eye.
swelling in the deep layers of your skin.

Pregnancy & Breastfeeding Precautions While Taking Taltz

If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Your doctor will discuss the possible risks and benefits of using this medicine during pregnancy and breast-feeding.

Non-Pharmacological Treatments & Advices

Get enough sleep, Sleep and immunity are closely tied.
Eat more whole plant foods & healthy fats.
Eat more fermented foods.
Limit added sugars.
Engage in moderate exercise.
Stay hydrated.
Manage your stress levels.

Warnings & Special Precautions while Taking Taltz

Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Infections
Treatment with Taltz is associated with an increased rate of infections such as upper respiratory tract infection, oral candidiasis, conjunctivitis, and tinea infections.
Taltz should be used with caution in patients with clinically important chronic infection or a history of recurrent infection. Patients should be instructed to seek medical advice if signs or symptoms suggestive of an infection occur. If an infection develops, patients should be carefully monitored and Taltz discontinued if the patient is not responding to standard therapy or if the infection becomes serious. Taltz should not be resumed until the infection resolves.
Taltz must not be given to patients with active tuberculosis (TB). Anti-TB therapy prior to initiation of Taltz in patients with latent TB should be considered.
Hypersensitivity
Serious hypersensitivity reactions, including some cases of anaphylaxis, angioedema, urticaria and, rarely, late (10-14 days following injection) serious hypersensitivity reactions including widespread urticaria, dyspnea and high antibody titres have been reported. If a serious hypersensitivity reaction occurs, administration of Taltz should be discontinued immediately and appropriate therapy initiated.
Inflammatory bowel disease (including Crohn's disease and ulcerative colitis)
Cases of new or exacerbations of inflammatory bowel disease have been reported with ixekizumab. Ixekizumab is not recommended in patients with inflammatory bowel disease. If a patient develops signs and symptoms of inflammatory bowel disease or experiences an exacerbation of pre-existing inflammatory bowel disease, ixekizumab should be discontinued and appropriate medical management should be initiated.
Immunisations
Taltz should not be used with live vaccines. No data are available on the response to live vaccines; there are insufficient data on response to inactive vaccines.
Excipients
This medicinal product contains less than 1 mmol sodium (23 mg) per 80 mg dose, that is to say essentially “sodium-free”.

Storage Conditions of Taltz

Store in a refrigerator (2 °C to 8 °C).
Don’t freeze.
Keep this medicine out of the sight and reach of children.
Store in the original package to protect from moisture.
Do not use this medicine after the expiry date which is stated on the box/blisters/label.
The expiry date refers to the last day of the month.

For More Information About Ixekizumab

Ask your physician or pharmacist
Visit Official Website for SFDA
Or For More Information About Ixekizumab
Or For More Information About Ixekizumab .

Taltz

Taltz

1 result for Taltz